2 results match your criteria: "University of North Carolina at Chapel Hill 27599-7435[Affiliation]"
Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells.
J Infect Dis
April 2008
Departments of Medicine, University of North Carolina at Chapel Hill 27599-7435, USA.
Background: Novel therapeutic approaches are needed to attack persistent proviral human immunodeficiency type 1 (HIV-1) infection. Hexamethylbisacetamide (HMBA), a hybrid bipolar compound, induces expression of the HIV-1 promoter in the long terminal repeat (LTR) region in a Tat-independent manner but mimics the effect of Tat, overcoming barriers to LTR expression and increasing the processivity of LTR transcription complexes.
Methods: We studied alterations in cellular factors and their LTR occupancy induced by HMBA in models of latent HIV-1 infection.
Sports injury and arthritis.
N C Med J
March 2008
Department of Epidemiology, University of North Carolina at Chapel Hill 27599-7435, USA.